DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
PRECISION BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.19+0.42 (+7.28%)
Close on Oct 19, 2026
- Market cap
- $160.05M
- P/E (TTM)
- –
- Dividend yield
- –
PRECISION BIOSCIENCES INC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q4 21 | Q3 21 | Q2 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Segment | $0 | $10.84M | $34.20M | $13.00K | $18.00K | $29.00K | $638.00K | $576.00K | $49.90M | – | – | – | – | -100.0% |
| Therapeutics | – | – | – | – | – | – | – | – | – | $5.36M | $22.80M | $67.89M | – | – |
| Food | – | – | – | – | – | – | – | – | – | $977.00K | $1.24M | $918.00K | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q4 21 | Q3 21 | Q2 21 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Segment | -$19.16M | -$9.08M | $12.51M | -$20.67M | -$21.88M | -$22.11M | -$24.85M | -$21.28M | $24.15M | – | – | – | -12.4% |
| Therapeutics | – | – | – | – | – | – | – | – | – | -$12.05M | $4.68M | $46.53M | – |
| Food | – | – | – | – | – | – | – | – | – | -$673.00K | -$491.00K | -$1.04M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Precision Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.